Tarsus Pharmaceuticals, Inc. TARS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s operating cash flow?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating cash flow of -$24.65M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s operating cash flow changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s operating cash flow decreased by 19.4% year-over-year, from -$20.65M to -$24.65M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating cash flow?
- Over 2 years (2022 to 2024), Tarsus Pharmaceuticals, Inc.'s operating cash flow has grown at a 30.1% compound annual growth rate (CAGR), from -$49.03M to -$83.03M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.